The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis
Williams, G. T., Smith, C. A., Spooncer, E., Dexter, T. M., & Taylor, D. R. (1990) · Nature · doi:10.1038/343076a0 · Cited by 895
Witthuhn, B. A., Silvennoinen, O., Miura, O., Lai, K. S., Cwik, C., Liu, E. T., & Ihle, J. N. (1994) · Nature · doi:10.1038/370153a0 · Cited by 613
Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2
Johnston, J. A., Kawamura, M., Kirken, R. A., Chen, Y.-Q., Blake, T. B., Shibuya, K., Ortaldo, J. R., McVicar, D. W., & O'Shea, J. J. (1994) · Nature · doi:10.1038/370151a0 · Cited by 595
Defective T cell receptor signaling and CD8+ thymic selection in humans lacking Zap-70 kinase
Arpaia, E., Shahar, M., Dadi, H., Cohen, A., & Rolfman, C. M. (1994) · Cell · doi:10.1016/0092-8674(94)90368-9 · Cited by 554
Self-citationWilks, A. F., Harpur, A. G., Kurban, R. R., Ralph, S. J., Zürcher, G., & Ziemiecki, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.4.2057 · Cited by 528
Nadler, L. M., Anderson, K. C., Marti, G., Bates, M., Park, E., Daley, J. F., & Schlossman, S. F. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.1.244 · Cited by 486
Differentiation-Linked Leukemogenesis in Lymphocytes
Greaves, M. F. (1986) · Science · doi:10.1126/science.3535067 · Cited by 338
JAK2, a third member of the JAK family of protein tyrosine kinases.
Harpur, A. G., Andres, A. ‐., Ziemiecki, A., Aston, R. R., & Wilks, A. F. (1992) · PubMed · Cited by 306
Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases
Osherov, N., & Levitzki, A. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.1047b.x · Cited by 281
Self-citationBiotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases
Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Tuel-Ahlgren, L., Chelstrom, L. M., Burkhardt, A., Bolen, J., & Myers, D. E. (1995) · Science · doi:10.1126/science.7531365 · Cited by 271
Cited by
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
“For example, in a model of human acute lymphocytic leukemia (ALL), the tyrphostin AG490 inhibited proliferation of ALL cells in mice without adverse e ects on normal hematopoiesis (Meydan et al., 1996).”
BackgroundCatlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationNF-κB and STAT3 – key players in liver inflammation and cancer
He, G., & Karin, M. (2011) · Cell Research · doi:10.1038/cr.2010.183 · Cited by 1,197
de Jonge, W. J., van der Zanden, E. P., The, F. O., Bijlsma, M. F., van Westerloo, D. J., Bennink, R. J., Berthoud, H.-R., Uematsu, S., Akira, S., van den Wijngaard, R. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1229 · Cited by 1,074
Digicaylioglu, M., & Lipton, S. A. (2001) · Nature · doi:10.1038/35088074 · Cited by 923
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 770
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Yoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P., Groopman, J. D., Manning, J. E., Harris, C. C., & Herman, J. G. (2001) · Nature Genetics · doi:10.1038/ng0501-29 · Cited by 722
The JAK-STAT pathway at 30: Much learned, much more to do
Philips, R. L., Wang, Y., Cheon, H., Kanno, Y., Gadina, M., Sartorelli, V., Horvath, C. M., Darnell, J. E., Stark, G. R., & O’Shea, J. J. (2022) · Cell · doi:10.1016/j.cell.2022.09.023 · Cited by 720
Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N., et al. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1309 · Cited by 719
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633
STAT proteins: From normal control of cellular events to tumorigenesis
Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., & Russo, A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10364 · Cited by 610
Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Sansone, P., & Bromberg, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8907 · Cited by 515
Bharti, A. C., Donato, N., & Aggarwal, B. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3863 · Cited by 508
The chemokine SDF‐lα triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway
Vila‐Coro, A. J., Rodríguez‐Frade, J. M., De Ana, A. M., Moreno‐Ortíz, M. C., Martínez‐A., C., & Mellado, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.13.1699 · Cited by 506
Peeters, P., Raynaud, S. D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den Berghe, H., et al. (1997) · Blood · doi:10.1182/blood.v90.7.2535 · Cited by 491
He, H., Venema, V. J., Gu, X., Venema, R. C., Marrero, M. B., & Caldwell, R. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.35.25130 · Cited by 488
STAT3 as a target for inducing apoptosis in solid and hematological tumors
Al Zaid Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 487
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger, M. W. N., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 482
Saxena, N. K., Sharma, D., Ding, X., Lin, S., Marra, F., Merlin, D., & Anania, F. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3075 · Cited by 469
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
Hes binding to STAT3 mediates crosstalk between Notch and JAK–STAT signalling
Kamakura, S., Oishi, K., Yoshimatsu, T., Nakafuku, M., Masuyama, N., & Gotoh, Y. (2004) · Nature Cell Biology · doi:10.1038/ncb1138 · Cited by 423
Hunter, T. (1998) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1998.0228 · Cited by 410
The BCR-ABL Story: Bench to Bedside and Back
Wong, S., & Witte, O. N. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104753 · Cited by 399
Shouda, T., Yoshida, T., Hanada, T., Wakioka, T., Oishi, M., Miyoshi, K., Komiya, S., Kosai, K.-I., Hanakawa, Y., Hashimoto, K., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13568 · Cited by 395
Jaks, STATs, Cytokine Signal Transduction, and Immunoregulation: Are We There Yet?
O'Shea, J. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80505-1 · Cited by 386
A Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
Rahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377
Diverse intracellular pathogens activate type III interferon expression from peroxisomes
Odendall, C., Dixit, E., Stavru, F., Bierne, H., Franz, K. M., Durbin, A. F., Boulant, S., Gehrke, L., Cossart, P., & Kagan, J. C. (2014) · Nature Immunology · doi:10.1038/ni.2915 · Cited by 374
Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J. (2010) · Biochemical Journal · doi:10.1042/bj20100784 · Cited by 372
Iwamaru, A., Szymanski, S., Iwado, E., Aoki, H., Yokoyama, T., Fokt, I., Hess, K., Conrad, C., Madden, T., Sawaya, R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210031 · Cited by 370
The myocardial JAK/STAT pathway: From protection to failure
BOENGLER, K., HILFIKERKLEINER, D., DREXLER, H., HEUSCH, G., & SCHULZ, R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.002 · Cited by 362
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
The EGF receptor as central transducer of heterologous signalling systems
Zwick, E., Hackel, P. O., Prenzel, N., & Ullrich, A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01373-5 · Cited by 343
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2
Ding, L., Xu, Y., Zhang, W., Deng, Y., Si, M., Du, Y., Yao, H., Liu, X., Ke, Y., Si, J., et al. (2010) · Cell Research · doi:10.1038/cr.2010.79 · Cited by 341
Signal transducer and activator of transcription proteins in leukemias
Benekli, M., Baer, M. R., Baumann, H., & Wetzler, M. (2003) · Blood · doi:10.1182/blood-2002-04-1204 · Cited by 325
Weber-Nordt, R., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V, Mertelsmann, R., & Finke, J. (1996) · Blood · doi:10.1182/blood.v88.3.809.809 · Cited by 314
The Jak-Stat pathway in normal and perturbed hematopoiesis
Ward, A. C., Touw, I., & Yoshimura, A. (2000) · Blood · doi:10.1182/blood.v95.1.19 · Cited by 313
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2
Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J. C., Williams, I. R., Lee, C.-K., Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00067-8 · Cited by 303
Relloso, M., Puig-Kröger, A., Pello, O. M., Rodríguez-Fernández, J. L., de la Rosa, G., Longo, N., Navarro, J., Muñoz-Fernández, M. A., Sánchez-Mateos, P., & Corbí, A. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2634 · Cited by 300
Ding, B. B., Yu, J. J., Yu, R. Y.-L., Mendez, L. M., Shaknovich, R., Zhang, Y., Cattoretti, G., & Ye, B. H. (2008) · Blood · doi:10.1182/blood-2007-04-087734 · Cited by 298
Pollack, B. P., Kotenko, S. V., He, W., Izotova, L. S., Barnoski, B. L., & Pestka, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31531 · Cited by 290
An essential role of the JAK-STAT pathway in ischemic preconditioning
Xuan, Y.-T., Guo, Y., Han, H., Zhu, Y., & Bolli, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161283798 · Cited by 285
Pellegrini, S., & Dusanter‐Fourt, I. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00615.x · Cited by 281
Role of NAD(P)H Oxidase in Angiotensin II–Induced JAK/STAT Signaling and Cytokine Induction
Schieffer, B., Luchtefeld, M., Braun, S., Hilfiker, A., Hilfiker-Kleiner, D., & Drexler, H. (2000) · Circulation Research · doi:10.1161/01.res.87.12.1195 · Cited by 273
Takemoto, S., Mulloy, J. C., Cereseto, A., Migone, T.-S., Patel, B. K. R., Matsuoka, M., Yamaguchi, K., Takatsuki, K., Kamihira, S., White, J. D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13897 · Cited by 270
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
Burke, W. M., Jin, X., Lin, H.-J., Huang, M., Liu, R., Reynolds, R. K., & Lin, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204990 · Cited by 269
The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2
Reiter, A., Walz, C., Watmore, A., Schoch, C., Blau, I., Schlegelberger, B., Berger, U., Telford, N., Aruliah, S., Yin, J. A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4263 · Cited by 269
Stankoff, B., Aigrot, M.-S., Noël, F., Wattilliaux, A., Zalc, B., & Lubetzki, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09221.2002 · Cited by 262
Contri, A., Brunati, A. M., Trentin, L., Cabrelle, A., Miorin, M., Cesaro, L., Pinna, L. A., Zambello, R., Semenzato, G., & Donella-Deana, A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522094 · Cited by 261
Pang, M., Ma, L., Gong, R., Tolbert, E., Mao, H., Ponnusamy, M., Chin, Y. E., Yan, H., Dworkin, L. D., & Zhuang, S. (2010) · Kidney International · doi:10.1038/ki.2010.154 · Cited by 260
Ungureanu, D., Saharinen, P., Junttila, I., Hilton, D. J., & Silvennoinen, O. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3316-3326.2002 · Cited by 260
Puthier, D., Bataille, R., & Amiot, M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199912)29:12<3945::aid-immu3945>3.0.co;2-o · Cited by 254
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor
Thompson, J. E., Cubbon, R. M., Cummings, R. T., Wicker, L. S., Frankshun, R., Cunningham, B. R., Cameron, P. M., Meinke, P. T., Liverton, N., Weng, Y., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00106-3 · Cited by 234
Nielsen, M., Kaltoft, K., Nordahl, M., Röpke, C., Geisler, C., Mustelin, T., Dobson, P., Svejgaard, A., & Ødum, N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6764 · Cited by 220
STAT signaling in the pathogenesis and treatment of leukemias
Lin, T. S., Mahajan, S., & Frank, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203486 · Cited by 205
The complex STATes of astrocyte reactivity: How are they controlled by the JAK-STAT3 pathway?
Ceyzériat, K., Abjean, L., Carrillo-de Sauvage, M.-A., Ben Haim, L., & Escartin, C. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.05.043 · Cited by 185
In vivo activation of JAK2/STAT‐3 pathway during angiogenesis induced by GM‐CSF
Valdembri, D., Serini, G., Vacca, A., Ribatti, D., & Bussolino, F. (2002) · The FASEB Journal · doi:10.1096/fj.01-0633fje · Cited by 144
Weerasinghe, P., Garcia, G., Zhu, Q., Yuan, P., Feng, L., Mao, L., & Jing, N. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.1.129 · Cited by 95
Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation
Fujinaka, Y., Takane, K., Yamashita, H., & Vasavada, R. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702607200 · Cited by 92
Biethahn, S., Alves, F., Wilde, S., Hiddemann, W., & Spiekermann, K. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00017-x · Cited by 74
JAK2 inhibition prevents innate immune responses and rescues animals from sepsis
Peña, G., Cai, B., Deitch, E. A., & Ulloa, L. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0628-z · Cited by 69
Lin, L., Benson, D. M., DeAngelis, S., Bakan, C. E., Li, P., Li, C., & Lin, J. (2012) · International Journal of Cancer · doi:10.1002/ijc.26152 · Cited by 66
Fatih, N., Camberlein, E., Island, M. L., Corlu, A., Abgueguen, E., Détivaud, L., Leroyer, P., Brissot, P., & Loréal, O. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0588-3 · Cited by 59
DNA‐Binding Small Molecules as Inhibitors of Transcription Factors
Leung, C., Chan, D. S., Ma, V. P., & Ma, D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21266 · Cited by 58
Eufemi, M., Cocchiola, R., Romaniello, D., Correani, V., Di Francesco, L., Fabrizi, C., Maras, B., & Schininà, M. E. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.01.007 · Cited by 39
AG490: An inhibitor of hepcidin expression in vivo
Zhang, S.-P. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i45.5032 · Cited by 35
Metadata
- Authors
- Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., & Roifman, C. M.
- Venue
- Nature
- Published
- 1996-02
- Volume
- 379
- Issue
- 6566
- Pages
- 645-648
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2127048642
- Cited by
- 897
- References
- 21
- FWCI
- 71.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.